Finance

Vaccine developer reports loss of $0.06 per share

Published in Vaccine Weekly, November 30th, 2005

Avant Immunotherapeutics, Inc., (AVAN) reported financial results for the third quarter and 9 months ended September 30, 2005 and provided a clinical pipeline update.

For the quarter ended September 30, 2005, Avant reported a net loss of $4.5 million, or $.06 per share, compared to a net loss of $3.7 million, or $.05 per share, for the third quarter of 2004. Avant reported cash and cash equivalents of $22 million at September 30, 2005.

Revenues during the third quarter of 2005 were $846,322 compared to revenues of $527,510 for the same period last year. Total operating expenses for the quarter were $5.5 million compared to $4.3 million in the same...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-11-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry